Index

Locators in italic refer to figures; those in bold to tables

a
AASM see American Academy of Sleep Medicine
acamprosate 93, 125
accelerometry 172, 173, 179, 230
acceptance-based therapy (ACT), insomnia 149
acetazolamide 108, 166, 285
acetylcholine/cholinergic drugs 84, 85–88, 87
acid maltase deficiency 257
actigraphy 172, 173, 179, 230
adenosine 78, 96, 99–100
ADHD see attention deficit hyperactivity disorder
ADNFLE see autosomal dominant frontal lobe epilepsy
adrenergic drugs 84, 89–90
advanced sleep phase syndrome (ASPS) 174–175
age changes, sleep architecture/quality 26, 62, 213
circadian rhythm 170
excessive daytime sleepiness 4
insomnia 66, 146
insufficient sleep syndrome 139
narcolepsy 132
obstructive sleep apnoea 157
parasomnia 68
REM sleep behaviour disorder 9, 185
shift work intolerance 176, 179
agomelatine 94, 104, 329
AHI (Apnoea–Hypopnoea Index) 157, 159, 160, 245, 322
alcohol habits
history-taking 5, 9
insomnia 147, 147, 150
obstructive sleep apnoea 157
pharmacological treatments 64, 65, 68
RLS/PLMD 199
alerting antidepressants 74, 79
alertness see vigilance; wakefulness
alternating leg muscle activation (ALMA) 19, 50
Alzheimer dementia (AD) 236
diagnostic criteria 51
brain systems affecting sleep/wakefulness 86
sleep disturbance in 178, 229–230
amantadine 93, 106, 115
American Academy of Sleep Medicine (AASM) guidelines
circadian rhythm sleep–wake disorders 174
objective tests use 34, 36
obstructive sleep apnoea 160
periodic limb movement disorder 193–194, 199
polysomnography 13, 15, 16–17, 19, 20, 22, 23
American Heart Association, stroke guidelines 309

Edited by Sebastiaan Overeem and Paul Reading.
© 2018 John Wiley & Sons Ltd. Published 2018 by John Wiley & Sons Ltd.
amitriptyline 66, 89, 104
insomnia 151
Parkinson’s disease 221
RLS/PLMD 322
amphetamines
excessive daytime sleepiness 74, 75, 76–78, 79
myotonic dystrophy 247
narcolepsy 132
neuromuscular disease 259, 260
sleep impacts 89, 105
amyotrophic lateral sclerosis (ALS) 51, 93, 106
analgesics, sleep impacts 94, 119–120
angiotensin converting enzyme (ACE) inhibitors 101
antidepressants 65–66
excessive daytime sleepiness 74, 75, 79
parasomnias 69
Parkinson’s disease 217
sleep impacts 104–105
see also SSRIs; tricyclic antidepressants; and see specific drugs by name
anti-epileptic drugs, sleep impacts 95–96, 99, 105–106
anti-histamines 88–91, 95, 102, 196
anti-inflammatory drugs, sleep impacts 101, 120–121
antimalarial drugs, sleep impacts 101, 115
antimicrobial drugs, sleep impacts 101, 114–117
anti-NMDA receptor encephalitis 332, 335, 336, 337
antipsychotic agents, sleep impacts 92, 103
antiviral medications, sleep impacts 101, 115–117
anxiety-related insomnia 146, 150, 273, 328
pharmacological treatments 64, 65, 67, 69
vicious circles 145, 146
anxiolytic drugs 73, 103; see also specific drugs by name
apnoea see obstructive sleep apnoea
Apnoea–Hypopnoea Index (AHI) 157, 159, 160, 245, 322
APOE-4 gene, Alzheimer’s disease 230
armodafinil 77–78
aromatase inhibitors, sleep impacts 101, 123
arousal disorders
insomnia as 62, 84, 145, 150
parasomnias 68–69
stroke 306–307, 311–312
arterial blood gases (ABG), neuromuscular disorders 255
ascending reticular activating system 84
ASPS (advanced sleep phase syndrome) 174–175
atomoxetine 79, 105
attention deficit hyperactivity disorder 173, 195, 197, 198
automated computer scoring (ACS), sleep apnoea 160
autonomic nervous system 100
autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) 279–280, 283–286
b
barbiturates 63, 64, 94, 99, 102, 105, 286
behavioural approaches
excessive daytime sleepiness 132
insomnia 147, 148, 151
narcolepsy 135–136
obstructive sleep apnoea 160
sleep disturbances in headache disorders 273
sleep disturbances in multiple sclerosis 322
see also cognitive behavioural therapy
behaviourally induced insufficient sleep syndrome see insufficient sleep syndrome
benign epilepsy of childhood with centrottemporal spikes (BECT) 277, 279, 280–281, 284, 286
benzodiazepines 63, 64
excessive daytime sleepiness 5
GABA-ergic effects 84, 98
headache disorders 273
insomnia 148
parasomnias 68–69
RLS/PLMD 204
Berlin Sleep Questionnaire 52, 53, 271
beta-blockers, sleep impacts 90, 94, 102
BiPAP (bi-level positive airway pressure) 246
body mass index (BMI) 38, 134, 159, 266, 303–305
botulinum toxin therapy 222
brain injury see traumatic brain injury
brain systems affecting sleep/wakefulness 83–96, 86
brain tumours 51, 329–332, 338
breathing disorders see sleep disordered breathing
bright light therapy 175, 176
bruxism 50, 91, 104, 268
history-taking 5, 8
polysomnography 16, 19, 20
bulbar poliomyelitis 257
bupropion 69, 79, 105

C
caffeine 75, 78, 100, 147, 150
calcium channels, voltage-gated 95, 118–119
cancer see tumours/cancer
capnography 15
CAPs (cyclic alternating patterns) 19, 278
carbohydrate craving, narcolepsy 134
cardiovascular disease
shift work disorder 175
and sleep disordered breathing 155, 157, 163–164
see also stroke
cataplexy 6, 40, 55, 132–133, 136, 331, 333
catathrenia 49
CBT see cognitive behavioural therapy
central disorders of hypersomnolence 129, 130, 130; see also hypersomnia; narcolepsy
central hypoventilation 49, 163, 165, 311
paraneoplastic syndromes 332, 333, 337, 338
central nervous system see CNS
central sleep apnoea (CSA) 155, 159, 162–166, 164
diagnostic criteria 49
diagnostic criteria 49
diagnostic strategies/classifications 294, 297
multiple sclerosis 321–322
neuromuscular disorders 251
stroke 302, 306, 309
cerebellar ataxias 51
cerebrovascular diseases 51
chemotherapy drugs, sleep impacts 122–125
Cheyne Stokes breathing (CSB) 198
central sleep apnoea 162, 163, 164, 164, 165, 166
neuromuscular disorders 251
stroke 302, 309, 311
CHRNA4 gene, epilepsy 286
cholinergic drugs 84, 85–88, 87
chronic obstructive pulmonary disease (COPD) 256
chronotherapy 174
chronotype 15, 53, 170, 172, 178
circadian rhythm sleep–wake disorders (CRSWDs) 169–170, 178–179
accelerometry/actigraphy 172, 173, 179
advanced sleep phase syndrome 174–175
Alzheimer’s disease 230
changes with age 170
delayed sleep phase syndrome 172–174
dementia with Lewy Bodies 231
diagnostic criteria 48, 49, 170–171
epidemiology 172, 174
free running 177–178
headache disorders 267
history-taking 171
investigations 171–172, 173
irregular sleep–wake rhythm disorder 178
jet lag 176–177
melatonin 66
shift work 175–176
sleep diaries 171, 174, 177, 179
traumatic brain injury see traumatic brain injury
traumatic brain injury 293, 295
clinical scales, parasomnias 186–188
clinical interviews 52, 54
myotonic dystrophy 245
narcolepsy 131

clinophobia 6
clonazepam 63, 63, 204, 323, 331
parasomnias 68–69, 70
Parkinson’s disease 220, 221, 222, 223
clonidine 69, 89, 109
cluster headache 269, 270
CNS stimulants see stimulant medications
CNS tumours 51, 329–332, 338
cognitive behavioural therapy (CBT) 57, 62, 65, 148–149, 151, 273
co-morbidity, sleep disorders 54–55
headache 265–266, 273
insomnia 143–144, 146, 148, 151
RLS/PLMD 195
complex partial seizures 9
concentration and memory problems
benign epilepsy of childhood 281
clinical interviews 131
drug impacts 64, 65, 88, 102, 106, 115, 125
excessive daytime sleepiness 4
insufficient sleep syndrome 139
insomnia 144
narcolepsy 5, 133, 134
shift work 175
sleep-disordered breathing 158, 301, 308, 337
stroke 307
confusional arousals 9, 50, 184, 221, 231, 283
congenital myopathies 257
continuous positive airway pressure (CPAP) 55, 56, 57
central sleep apnoea 165–166
headache disorders 272–273
myotonic dystrophy 246, 247, 249
neuromuscular disorders 257–260, 260
obstructive sleep apnoea 158, 160–161
Parkinson’s disease 222
polysomnography 14
continuous spikes and waves during sleep (CSWS) 277, 279, 281–282
COPD (chronic obstructive pulmonary disease) 256
corticosteroids
Landau-Kleffner syndrome 287
sleep impacts 94, 100, 101, 120
CPAP see continuous positive airway pressure
CRSWDs see circadian rhythm sleep–wake disorders
CSA see central sleep apnoea
CSWS see continuous spikes and waves during sleep
cyclic alternating patterns (CAPs) 19, 278
cyclopentolate eye drops 88
cytochrome P450 system, melatonin metabolism 94
d delayed sleep phase syndrome (DSPS) 7, 8, 56, 172–174
dementia with Lewy bodies (DLB) 212, 230–232, 236
dental devices 161–162, 260
depression
c-co-morbidity with sleep disturbances 173, 175, 273
sleep disturbance as risk-factor 62, 143, 146
dextroamphetamine 76
dextromethorphan, sleep impacts 93, 112
diabetes, and sleep disordered breathing 155
diagnostic strategies/classifications 47, 48, 49–51, 54–58; see also International Classification of Sleep Disorders; objective measurement; polysomnography; questionnaires
diaphragmatic pacing devices 260
diaries see sleep diaries
diazepam 63, 63, 68, 287
dim light melatonin onset (DLMO) 174
DLB (dementia with Lewy bodies) 212, 230–232, 236
dopamine/dopaminergic drugs
brain systems affecting sleep/wakefulness 84, 91–92, 86
RLS/PLMD 196, 197, 200–203, 202
sleep disorders in Parkinson’s disease 211, 214
doxazosin, sleep impacts 89, 108

doxepin 66, 104, 151
dream-like experiences 5, 6, 133–134; see also violent dream enactment
drugs see pharmacological treatments; sleep physiology (effects of medication)
DSPS (delayed sleep phase syndrome) 7, 8, 56, 172–174
Duchenne’s muscular dystrophy 257
dysfunctional thoughts 145, 146, 148–149; see also rumination

eating see food
EDS see excessive daytime sleepiness
electrical status epilepticsus in sleep (ESES) 277, 285–287
electrocardiography (ECG) 13, 22, 24
electrochemical signalling, impacts of medication 95–96
electroencephalography (EEG) 13, 16, 19, 27, 28
brain systems affecting sleep/wakefulness 84
epilepsy 187, 278, 282–284, 283, 286
obstructive sleep apnoea 159, 160
parasomnias 189, 190
Parkinson’s disease 218
vigilance 32
see also polysomnography
electromyography (EMG) 15, 16, 18, 19, 27
obstructive sleep apnoea 159
Parkinson’s disease 218
see also polysomnography
end tidal carbon dioxide (EtCO2) 255, 256
epidemiology of sleep disorders
central sleep apnoea 164
circadian rhythm sleep–wake disorders 172, 174
epilepsy 278–279
headache disorders 266–268
idiopathic hypersomnia 136
insomnia 143, 144
insufficient sleep syndrome 139
Kleine–Levin syndrome 137–138
myotonic dystrophy 243, 247
narcolepsy 132
obstructive sleep apnoea 157, 159
Parkinson’s disease 212–213
traumatic brain injury 291–292, 292
epigenetic mechanisms, insomnia 145
epilepsy 277
clinical features 279–282
diagnostic criteria 51
differentiation from parasomnias 183–184
epidemiology 278–279
history-taking 8, 9, 10
investigations 282–285, 283
management 285–287
polysomnography 28
and sleep disturbances 277, 287
and stage of sleep 277–278
see also nocturnal frontal lobe epilepsy/sleep hypermotor epilepsy (NFLE/SHE)
Epworth Sleepiness Scale (ESS) 38, 48–50, 52
circadian rhythm sleep–wake disorders 171
excessive daytime sleepiness 73
multiple sclerosis 320
myotonic dystrophy 244
narcolepsy 131
neuromuscular disorders 253
obstructive sleep apnoea 158
Parkinson’s disease 214–215
stroke 304, 306
traumatic brain injury 293
ergot derivatives, RLS/PLMD 202
ESES (electrical status epilepticsus in sleep) 277, 285–287
event-related hypoxaemia, neuromuscular disorders 253
excessive daytime sleepiness (EDS) 4–6, 75–76, 140
cancer patients 328, 330, 331
definitions 73, 130
diagnostic criteria 41, 53, 134, 293
diagnostic algorithm 74
distinction from fatigue 4, 10, 73, 319–320, 324
history-taking 4–7, 130–131
excessive daytime sleepiness (EDS) (cont’d)
  Kleine–Levin syndrome 139
  management 74, 293
  multiple sclerosis 319–320
  myotonic dystrophy 244–9, 246
  objective measurement tests 31–32, 33, 35, 40, 41, 42
  obstructive sleep apnoea 158
  paraneoplastic syndromes 333–335, 336
  Parkinson’s disease 5, 6, 74, 211–215, 217, 223
  pharmacological treatments 73–79, 74
  stroke 306–307
  as symptom of narcolepsy 132
  traumatic brain injury 292–293, 294
  see also hypersomnia; narcolepsy
  exploding head syndrome 9, 50, 268
  extrapyramidal diseases, diagnostic criteria 51

f
  famotidine, sleep impacts 89, 111
  fatal familial insomnia, diagnostic criteria 51
  fatigue 26, 41, 47, 54, 61, 73
  distinction from excessive daytime sleepiness 4, 10, 73, 319–320, 324
  multiple sclerosis 319–320, 321, 324
  traumatic brain injury 294, 295–296
  fibromyalgia, diagnostic criteria 51
  FLE (frontal lobe epilepsy) 184; see also epilepsy
  FLEP (Frontal Lobe Epilepsy and Parasomnia) Scale 187, 284
  flumazenil, sleep impacts 99, 125
  food
    excessive daytime sleepiness 132
    and insomnia 150
    narcolepsy 134
  Foster, Russell 169
  fragmented sleep
    Huntington’s disease 232, 233
    motor neurone disease 257
    narcolepsy 133, 135
    obstructive sleep apnoea 156
    parasomnias 67
    Parkinson’s disease 214
    polysomnography 26, 28, 135, 156
    free running circadian rhythm disorder 177–178
    Frontal Lobe Epilepsy and Parasomnia (FLEP) Scale 187, 284
    frontal lobe epilepsy (FLE) 184
    functional complaints 54

  g
  gabapentin 67
  gamma-aminobutyric acid (GABA)
    brain systems affecting sleep/wakefulness 84, 96–99, 97
    drugs impacting on 64, 65, 66–67, 86
  gastro-intestinal complaints, and insomnia 146
  genetics/genetic variations
    Alzheimer’s disease 230
    chronotypes 15, 53, 170, 172, 178
    circadian rhythm sleep–wake disorders 172
    epilepsy 283, 286
    insomnia 145
    narcolepsy 134
    Gibbs, E.L. and Gibbs, F.A. 277
    Glovinsky, P. 144
    glutamate/glutamatergic system 84, 85, 86, 87, 92–93
    guadeloupian parkinsonism 212

  h
  head banging 10, 20, 186
  head injuries see traumatic brain injury
  headache disorders 274
    co-morbidity with sleep disturbances 265–266, 273
    diagnostic criteria 51, 268–270, 269
    diagnostic algorithm 266, 272, 274
    epidemiology 266–268
    history-taking 270–271, 271
    investigations 270–272
    management 272–273
    questionnaires 271
    triggers 270
    see also migraine
herbal sleep aids 62
hereditary ataxias 233–236, 235
histamine/histaminergic drugs 84, 88–91, 95, 102, 196
history-taking see sleep history
HLA-DQB1 gene, narcolepsy 134
hormone treatments 100, 101, 117–118; see also melatonin
Huntington's disease 232–233, 236
hyper-arousal see arousal disorders
hypersomnia 31
brain tumours 330–331
central disorders of
hypersomnolence 130
definitions 130
diagnostic criteria 41, 49, 51
paraneoplastic syndromes 332, 333, 334, 334, 335
questionnaires 131
stroke 306–307, 312
traumatic brain injury 294
see also excessive brain injury
hypertension 157, 195, 266, 271, 302, 306, 308
medication impacts 84, 89, 90, 95, 100, 107–109
hypnagogic hallucinations 133, 136
hypnic headache 268–270, 269
hypnic jerks 19, 50, 186
hypocretin/orexin system
Huntington's disease 232
insomnia 151
Multiple Sleep Latency Test 42
multiple sclerosis 323, 324
myotonic dystrophy 246
narcolepsy 40, 43, 132, 134, 135
neuropathies 258
neuropharmacology 85, 93, 100
RLS/PLMD 196
stroke 307
traumatic brain injury 293, 297
tumours/paraneoplastic syndromes 330–335, 336, 338
hypoglossal nerve stimulators 260
hypopnoeas 251
hypotension, sleep impacts of
medication 110
hypothalamus 4, 5, 83, 84
hypoventilation disorders 155, 158, 159, 163, 165
cancer patients 332, 333, 337, 338
diagnostic criteria 49
neuromuscular disease 251–257, 259–261
Parkinson's disease 215, 222
polysomnography 15, 24
stroke 301, 311
see also respiratory depression
hypoxaemia, sleep 49, 252, 253, 256, 256

idiopathic hypersomnia (IH) 6–7, 129, 133
diagnostic criteria 40–41, 49, 51, 130, 137
epidemiology 136
excessive daytime sleepiness 73
management 77, 137
symptoms 136–137
see also narcolepsy
imaging see neuroimaging
immune system modulators, sleep impacts 101, 121
infections 101
inflammatory disorders 5, 7, 101
insomnia 143, 151
Alzheimer's disease 230
as arousal disorder 62, 84, 145, 150
cancer patients 328
cognitive behavioural therapy 148–149, 151
co-morbidity 143–144, 146, 148, 151
definitions 143, 307
and depression 62, 143, 146
diagnostic criteria 8, 49, 57, 143, 144
diagnostic algorithm 8, 8
epidemiology 143, 144
headache disorders 267, 273, 274
insomnia (cont’d)
  history-taking  7–8, 146–147, **147**
  management  148–151
  multiple sclerosis  321
  neurology  143–144, **145**
  paraneoplastic syndromes  337
  Parkinson’s disease  211, 213–214, 217–221
  pathophysiology  144–145
  pharmacological treatments  61–67, **63, 63**
  polysomnography  148
  sleep diaries  147–148
  sleep hygiene  149, **150**
  sleep impacts of medication  **103**
  stroke  8, 144, 307–308, 312
  3-P model  144–145, **145**
  traumatic brain injury  **294**, 296–297

Insomnia Severity Index  321

insufficient sleep syndrome  129
  diagnosis/diagnostic criteria  41
  epidemiology  139
  management  140
  see also delayed sleep phase syndrome

interictal epileptiform discharges (IEDs)  277, 278; see also epilepsy

International Classification of Sleep Disorders (ICSD-3)  47, 48, **49–50, 51**, 54, 58

  central disorders of
    hypersomnolence  129, 130, 134
    circadian rhythm sleep–wake
    disorders  170–171
    idiopathic hypersomnia  137
    insomnia  61, 143, **144**
    narcolepsy  134
  objective measurement tests  40
  RLS/PLMD  193–194, **194**, 195, 197
  shift work disorder  175
  see also diagnostic strategies/classification

International Restless Legs Severity Scale  53

iron deficiency, and RLS  197, 199, 204–205, 217, 322
irregular sleep–wake rhythm disorder  **49**, 170, 178

**j**
  jet lag  176–177
  juvenile myoclonic epilepsy (JME)
    clinical features  281
    investigations  284
    management  286

**k**
  K-complexes  13, 19, 230
  Kales, A.  13
  Karolinska Sleepiness Scale  293
  Kleine–Levin syndrome  129, 130, 137–139, 307
  diagnostic criteria  **49, 51**
  excessive daytime sleepiness  73–74

**l**
  lamotrigine  93
  Landau–Kleffner syndrome (LKS)  277, 279
  larks  170, 175
  levodopa  200–203, 214, 221, 234, 236
  lifestyle adjustments see behavioural approaches
  light, as zeitgeber/timekeeper  170; see also melatonin
  light–dark cycle  97
  limbic encephalitis  8
  lipid lowering drugs, sleep impacts  100, **111**
  loop gain  163
  loprazolam  **63, 64**
  lormetazepam  **63, 64**

**m**
  macular degeneration, sleep impacts of medication  122
  magnesium, glutamate/NMDA inhibition  92–93
  magnetic resonance imaging (MRI)
    excessive daytime sleepiness  5
    paraneoplastic syndromes  333–335, 334
Maintenance of Wakefulness Test (MWT) 31, 32, 33–35
AASM guidelines for use 36
diagnostic criteria 41
excessive daytime sleepiness 73
normative data 39
recommendations/interpretation 42, 43
mandibular advancement devices (MADs) 161–162, 260
maximum (peak) expiratory/inspiratory pressure 254
mazindol 74, 79
MCTQ (Munich Chronotype Questionnaire) 53
measurement see objective measurement;
polysomnography; questionnaires; and see specific instruments by name
MD see myotonic dystrophy
medication see pharmacological treatments
medullary ventilatory centre, central sleep apnoea 163
melatonin 56, 66
circadian rhythm sleep–wake disorders 170, 174, 175, 178
insomnia 151
light–dark cycle 97, 170
REM sleep behaviour disorder 69
sleep impacts of medication 89, 90
sleep regulators 93–94
memantine, sleep impacts 93, 106
memory problems see concentration and memory problems
methylphenidate
excessive daytime sleepiness 76–77, 79, 223, 293
idiopathic hypersomnia 137
myotonic dystrophy 247
narcolepsy 136
neuromuscular disease 260
Parkinson's disease 220
pleisomnia 295
sleep impacts 89–90, 105
stroke 310, 312
traumatic brain injury 295
methysergide, sleep impacts 91, 107
MFIS (Modified Fatigue Impact Scale) 320
microarousals, obstructive sleep apnoea 156, 157, 159
micro-sleeps, excessive daytime sleepiness 5
midazolam 68
migraine 265, 267
behavioural approaches/lifestyle adjustments 273
circadian rhythm sleep–wake disorders 267
diagnostic criteria 51, 268
diagnostic algorithm 272
history-taking 10
insomnia 267
restless legs syndrome 267
sleep impacts of medication 107
sleep-disordered breathing 266
triggers 270
see also headache disorders
mirtazapine 65, 151, 196, 217
mitotane, sleep impacts 101, 123
modafinil
Alzheimer's disease 230
cancer patients 334
circadian rhythm sleep–wake disorders 176
excessive daytime sleepiness 75, 76, 77–78, 79, 223, 246, 293
idiopathic hypersomnia 137
myotonic dystrophy 246, 247
narcolepsy 132, 136
neuromuscular diseases 259
Parkinson's disease 220
sleep impacts 89
stroke 310, 312
traumatic brain injury 295, 296, 297
Modified Fatigue Impact Scale (MFIS) 320
monoamine oxidase B (MAO-B) inhibitors 76, 79
motor disturbances 9–10, 215–216;
see also parasomnias; rhythmic movement disorders; sleep-related movement patterns
motor neurone disease 257
MRI see magnetic resonance imaging
Index

MSA see multiple system atrophy
MSLT see Multiple Sleep Latency Test
multiple sclerosis 319, 324
diagnostic criteria 51
diagnostic algorithm 320
excessive daytime sleepiness /fatigue 5, 319–320
insomnia 7, 144, 321
narcolepsy/neuromyelitis optica 323
RLS/PLMD 322–323
sleep impacts of medication 106
sleep-disordered breathing 321–322
Multiple Sleep Latency Test (MSLT) 31, 32–33, 40–41, 55
AASM guidelines for use 34
excessive daytime sleepiness 73
idiopathic hypersomnia 137
Kleine–Levin syndrome 138
myotonic dystrophy 245, 246, 246
narcolepsy 131, 134, 135, 135
normative data 38–39
paraneoplastic neurological syndromes 334
Parkinson's disease 218
recommendations/interpretation 42–43
traumatic brain injury 293
multiple system atrophy (MSA) 9–10, 212–215, 222
Munich Chronotype Questionnaire (MCTQ) 53
Munich Parasomnias Screening (MUPS) 52, 53
muscle relaxants, sleep impacts 107; see also benzodiazepines
MWT see Maintenance of Wakefulness Test
myasthenia gravis 258
myopathies 257–258
myotonic dystrophy (MD) 241, 242–243
diagnostic criteria 41
diagnostic algorithm 246
epidemiology 243, 247
investigations 245–246, 248
management 246–247, 246, 248–249
sleep disorders 244–245, 248
symptoms 243–244, 247
type 1 243–247, 246
type 2 247–249
n
nAChR gene 283
napping
excessive daytime sleepiness 4, 5, 74
and insomnia 7, 145, 150
narcolepsy 132
objective measurement tests 38
narcolepsy 4, 5, 6, 73, 75, 129
brain tumours 329–331
clinical interviews 131
diagnostic criteria 40, 51, 55, 129, 130, 134–135
epidemiology 132
investigations 130–132
management 132, 135–136
multiple sclerosis 323
nocturnal disturbances 10
objective measurement tests 33, 38, 39
pharmacological treatments 67, 75–76, 136
polysomnography 135, 135
symptoms 132–134
see also excessive daytime sleepiness
neurobiology of insomnia 145
neurocognitive model of insomnia 145
neurodegenerative diseases 229, 236
dementia with Lewy Bodies 212, 230–232, 236
excessive daytime sleepiness 74
hereditary ataxias 233–236, 235
Huntington's disease 232–233, 236
insomnia 7
narcolepsy 6
sleep disturbance as early/prodromal feature 62
see also Alzheimer's disease; multiple sclerosis; Parkinson's disease
neuroimaging, parasomnias 189; see also magnetic resonance imaging; positron emission tomography
neuromuscular disorders 251, 261
continuous positive airway pressure 257–260, 260
diagnostic criteria 51
investigations 253–256
management of sleep dysfunction 259, 259–261
motor neurone disease 257
myopathies/neuromuscular junction
disorders 257–258
neuropathies 258
pharmacological treatments 260–261
polysomnography 256, 258, 261
pulse oximetry 255–256, 256
sleep and breathing 251–256, 253, 259, 260, 261
sleep impacts of medication 107
see also myotonic dystrophy
neuromyelitis optica (NMO) 323
neuronal conduction, sleep impacts of
medication 95–96
neuropathies 258
neuropharmacology see pharmacological
treatments; sleep physiology (effects of
medication)
neurotransmitter systems 84, 85–96, 86
NFLE/SHE see nocturnal frontal lobe
epilepsy/sleep hypermotor epilepsy
nicotine, and insomnia 150
nicotinic agonists, sleep impacts 88
night owls 7, 15, 170, 175
night terrors 9, 68–69, 185, 187
NMO (neuromyelitis optica) 323
nocturnal dissociative seizures 185
nocturnal disturbances, history-taking 8–10
nocturnal frontal lobe epilepsy/sleep hypermotor epilepsy (NFLE/SHE)
clinical features of sleep disturbances 187, 279–280
clinical scales 186–188
diagnostic algorithms 189, 191, 191
differential diagnoses 184–186, 191
history-taking 186–188, 188
investigations 189–190, 282–284, 283
management 285–286
videos of events 189–191, 191
see also epilepsy
nocturnal hypoventilation see
hypoventilation disorders
nocturnal motor disturbances see motor
disturbances
nocturnal panic attacks 185
non-rapid eye movement arousal
parasomnias 183–186, 191
clinical features 187
history-taking 186, 188
see also parasomnias
non-rapid eye movement (NREM) sleep
epilepsy 277–278
history-taking 4, 9
neuromuscular disorders 251
noradrenaline/noradrenergic drugs 84, 86, 89–90
objective measurement, sleepiness/
vigilance 31–35, 34, 43
definitions 31–32
diagnostic criteria 40–41
normative data 38–40
parasomnias 186–188
recommendations/interpretation 37, 42–43
see also Maintenance of Wakefulness
Test; Multiple Sleep Latency Test;
polysomnography; Sustained Attention
to Response Task
obstructive sleep apnoea (syndrome)
5, 155, 166
Alzheimer’s disease 230
co-morbidity 55
definitions 155, 160
diagnostic criteria 47, 49
diagnostic algorithm 158
differential diagnoses 185
epidemiology 157
headache disorders 266–267, 271, 272–273, 274
health consequences 157
investigations 158–160
management 160–162
multiple sclerosis 321–322
neuromuscular disorders 251, 252, 253–254
objective tests 35
Parkinson’s disease 222
pathophysiology 155
polysomnography 24, 25, 156, 157
stroke 302, 306, 309
ODI (oxygen desaturation index), polysomnography 24
Ondine’s curse 337, 338
opioid medication
cancer patients 327, 328, 329
central sleep apnoea caused by 163, 164, 165, 322
everus daytime sleepiness caused by 223
for RLS/PLMD 200, 200, 203, 203, 205, 322
sleep impacts of medication 94, 112, 119, 125
orexin see hypocretin/orexin system
OSA see obstructive sleep apnoea (syndrome)
ovarian teratoma 332, 333, 335, 337
over the counter (OTC) sleep remedies 62, 88
owls 7, 15, 170, 175
oximetry testing 159, 165, 255–256, 256
oxygen desaturation index (ODI), polysomnography 24

P
panic attacks, nocturnal 185
paradoxical insomnia 7, 8, 53, 88
paramedian thalamic brain region 8
paraneoplastic neurological syndromes (PNS) 332–338, 333, 334, 336
parasomnias 191
diagnostic algorithm 191, 191
diagnostic criteria 50
derential diagnoses 183–186, 191
headache disorders 268
history-taking 8, 9, 10, 186–188, 188
investigations 186–188, 189
Parkinson's disease 211
pharmacological treatments 67–69
polysomnography 14
videos of events 189–191, 191
see also non-rapid eye movement arousal parasomnias
parkinsonian syndromes (PSs), 58, 212, 214, 216, 216, 218, 223–224
Parkinson's disease 211–212, 223, 224
diagnostic criteria 41, 51
epidemiology of sleep disorders in
212–213
excessive daytime sleepiness 5, 6, 74,
211–12, 214–215, 217, 223
insomnia 213–214, 217–221
investigations 216, 216–217
management 217–223, 219–220
nocturnal motor disturbances 9–10,
215–216
polysomnography 218
questionnaires 52
REM sleep behaviour disorder 211–217,
222–223
RLS/PLMD 196, 217, 222
sleep disordered breathing 215, 222
sleep impacts of medication 92, 93,
105–106
paroxetine 69, 70, 104
PDE inhibitors see phosphodiesterase inhibitors
periodic limb movements see restless legs syndrome/periodic limb movement disorder (RLS/PLMD)
peripheral neuropathy 197, 234
personality traits, insomnia 145, 145
pharmacological treatments 61
drug plasma levels throughout night 63
excessive daytime sleepiness 73–79, 74
narcolepsy 67, 75–76, 136
neuromuscular disorders 260–261
obstructive sleep apnoea 162
parasomnias 67–68
REM sleep behaviour disorder 69
RLS/PLMD 5, 66, 149, 200, 200–204,
201–203
sleep-onset and sleep-maintenance insomnia 61–67
see also sedatives; sleep physiology (effects of medication) and see specific drugs by name
phosphodiesterase (PDE) inhibitors, sleep impacts 100, 102, 108, 109, 110, 113, 123
physiology of sleep see sleep physiology
pitolisant 40, 78, 132, 136
Pittsburg Sleep Quality Index (PSQI) 52, 52–53
pleiosomnia, in traumatic brain injury 293–295, 297; see also hypersomnia
PLMD see restless legs syndrome/periodic limb movement disorder
PNS see paraneoplastic neurological syndromes
polysomnography (PSG) 13–14, 28
Alzheimer’s disease 230
AASM guidelines 13, 15, 16–17, 19, 20, 22, 23
analysis/interpretation 24–26
circadian rhythm sleep–wake disorders 172
diagnostic criteria 53, 55, 56, 56
electrocardiography 22
indications 14
insomnia 148
investigations 189–190
narcolepsy 135, 135
neuromuscular disorders 256, 258, 261
NFLE/SHE 187
obstructive sleep apnoea 24, 25, 156, 159
parasomnias 190
Parkinson’s disease 213, 218
pointers/pitfalls 26–28, 27
REM sleep 21, 24
respiratory scoring 22–24, 23
RLS/PLMD 195, 196
scoring of sleep stages 18, 18–19
sleep-related movement patterns 19–20
sound recordings 22
see also video-polysomnography
pontomedullary brain region 5
positron emission tomography (PET), epilepsy 283–284
post-polio syndrome 257
post-traumatic insomnia see traumatic brain injury
potassium channels, voltage-gated 335
pramipexole 69, 106, 310, 313,
RLS/PLMD 201, 201, 202–203
prazosin 89, 108
pregabalin 67, 70, 151
multiple sclerosis 321, 322
RLS/PLMD 204, 205, 222, 261
sleep impacts 95, 106
pregnancy, 75, 77
magnesium 93
RLS/PLMD 195–196, 199
sleep impacts of medication 114
progressive supranuclear palsy (PSP) 212
prostaglandins 100, 101, 109, 111, 112, 114, 119, 120
proton pump inhibitors, sleep impacts 89, 111–112
PSG see polysomnography
PSP (progressive supranuclear palsy) 212
PSQI (Pittsburg Sleep Quality Index) 52, 52–53
psychogenic non-epileptic seizures/pseudoseizures 185
psychophysiological insomnia 47, 56–57, 62, 321; see also insomnia
psychostimulants see stimulant medications
pulmonary function tests (PFTs) 254–255
pulse oximetry 159, 165, 255–256, 256
pure sleep epilepsies 183–184
q
questionnaires 4, 47, 48–53, 52, 54

cancer patients 327
central disorders of hypersomnolence 131
headache disorders 271
insomnia 148
see also specific scales by name
quetiapine 66, 103, 151, 220, 221, 230
r
rapid eye movement (REM) sleep
Alzheimer’s disease 230
brain tumours 330
epilepsy 278
excessive daytime sleepiness 5, 6
Multiple Sleep Latency Test 32
neuromuscular disorders 251
parasomnias, pharmacological treatments 68–69
polysomnography 13, 21, 24
sleep impacts of medication 85–96, 86, 87
RBD see REM sleep behaviour disorder
reboxetine, sleep impacts 89, 105
Rechtschaffen, A. 13
relaxation therapy, for insomnia 149, 150
REM sleep see rapid eye movement sleep
REM sleep behaviour disorder (RBD)
Alzheimer’s disease 230
brain tumours 331–332
dementia with Lewy Bodies 231–232
diagnostic criteria 51
differential diagnoses 185
history-taking 9
Huntington’s disease 233
multiple sclerosis 323
myotonic dystrophy 245
neuromuscular disorders 251, 258
paraneoplastic neurological syndromes 333, 335
Parkinson’s disease 211–17, 222–223
pharmacological treatments 69
polysomnography 19, 20
questionnaires 52, 52
sleep specialists 58
respiratory depression 64, 94, 163, 164;
see also hypoventilation disorders
respiratory muscles, neuromuscular disorders 254–255
respiratory polygraphy (RPG) 159, 160
respiratory scoring,
polysomnography 22–24, 23
restless legs syndrome/periodic limb
movement disorder (RLS/PLMD) 193–194, 205
Alzheimer’s disease 230
definitions 199
diagnostic criteria 50, 51, 54, 194, 194–195, 198
differential diagnoses 186, 198
headache disorders 267
hereditary ataxias 234–236, 235
history-taking 4, 6, 10
Huntington’s disease 233
insomnia 7, 146, 147
investigations 197, 197–199
iron deficiency 197, 199, 204–205, 217
management 199–205
multiple sclerosis 322–323
myotonic dystrophy 245, 248
neuromuscular disorders 251
Parkinson’s disease 213, 217
pathophysiology 195–197
pharmacological treatments and augmentations 5, 66, 149, 200, 200–204, 201–203
polysomnography 16, 19–20, 26, 195, 196
stroke 308, 312–313
rhythmic movement disorders (RMD) 10, 19, 20, 186
rilotuzole, sleep impacts 93, 106
RLS/PLMD see restless legs syndrome/periodic limb movement disorder
road traffic accident risk, obstructive sleep
apnoea 157
ropinirole
RLS/PLMD 201, 201, 202–203
sleep impacts 106
stroke-related movement disorder 310, 313
rotigotine 106, 202–203, 221
RPG (respiratory polygraphy) 159, 160
rumination 57, 65, 145, 145, 146, 328
5
SCAs (spinocerebellar ataxias) 233–236, 235
SCN see suprachiasmatic nucleus
scopolamine, sleep impacts 88, 112
SDB see sleep disordered breathing
sedatives 62, 64, 66, 69
AASM guidelines 34
cancer patients 328, 329
dementia 230
excessive daytime sleepiness 74
headache disorders 272, 273
insomnia 151
multiple sclerosis 321
Parkinson’s disease 217, 220, 221, 223
RLS/PLMD 199, 203
sleep impacts 84, 85, 88–96, 98, 99, 101, 102, 103–125
stroke patients 309, 310, 312
see also benzodiazepines
selegiline 74, 75, 79, 104, 106
serotonin/serotonergic drugs 84, 90–91, 101; see also SNRIs; SSRIs; and see specific drugs by name

SF-36 (36-Item Short Form Health Survey) 52, 53

SHE see nocturnal frontal lobe epilepsy/sleep hypermotor epilepsy
shift work disorder 175–176
side-effects of drugs see sleep physiology (effects of medication)

Siffre, Michel 170

signal analysis, polysomnography 24, 26
signal-effect coupling, sleep impacts of medication 95–96
sildenafil, sleep impacts 84, 100, 109
SINFLE (Structured Interview for NFLE) 187

SKID (Structured Interview for Sleep Disorders) 52, 53

sleep apnoea headache 265, 268, 269; see also sleep disordered breathing

sleep attacks
impact of medication 92, 106
myotonic dystrophy 244
narcolepsy 4, 133
Parkinson’s disease 201, 213, 214, 220

sleep deprivation 9, 28
and dementia 230
and excessive daytime sleepiness 73, 74
objective tests 31, 33, 38, 39, 41, 42
parasomnias 68

sleep diaries
circadian rhythm sleep–wake disorders 171, 174, 177, 179
excessive daytime sleepiness 4
headache disorders 271–272
insomnia 147–148
polysomnography 15

sleep disordered breathing (SDB) 4, 99, 155, 166; see also central sleep apnoea; obstructive sleep apnoea
diagnostic criteria 41, 47, 49
headache disorders 266–267
hereditary ataxias 236
insomnia 146, 147
multiple sclerosis 321–322
myotonic dystrophy 245, 246, 246–249

narcolepsy 129, 134
neuromuscular disorders 251–256, 253, 259, 260, 261
paraneoplastic neurological syndromes 337
Parkinson’s disease 215, 222
polysomnography 14
stroke 301–311

Sleep-disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ) 253

Sleep EVAL questionnaire 52, 53
sleep factors 99, 100–101, 102

sleep history 3, 10
circadian rhythm sleep–wake disorders 171
diagnostic criteria 54, 56–57
excessive daytime sleepiness 4–7, 130–131
headache disorders 270–271, 271
insomnia 7–8, 146–147, 147
nocturnal disturbances 8–10
parasomnias 186–188, 188

sleep hygiene 54
insomnia 149, 150
narcolepsy 132
RLS/PLMD 199
treatments as diagnostic aids 57

sleep hypermotor epilepsy (SHE) see nocturnal frontal lobe epilepsy/sleep hypermotor epilepsy

sleep hypoxaemia 49, 252, 253, 256, 256

sleep latency 33; see also Multiple Sleep Latency Test

sleep-maintenance insomnia 61–67, 63, 63

sleep-onset insomnia 57, 61–67, 63, 63

sleep onset REM periods (SOREMPs)

Multiple Sleep Latency Test 33, 34, 38–41, 55, 131, 134, 135, 137, 334, 336

narcolepsy 134

sleep paralysis
cancer patients 330, 331, 334
diagnostic criteria 50
impact of medication 93
myotonic dystrophy 245
narcolepsy 5, 131, 133, 134
stroke patients 307
sleep physiology, effects of medication 83, 84–85, 102
brain systems 83–84
drug interactions 85
inhibition of arousal systems 84
insomnia 147
list of medications 103–125
neuronal conduction/signalling 95–96
non-REM sleep 96–101, 97
sleep factors/immune system modulatory drugs 100–101
wakefulness/REM sleep 84, 85–96, 86, 87
sleep questionnaires see questionnaires
sleep regulators 93–94
sleep-related epilepsies 183–184; see also epilepsy
sleep-related hypoventilation disorders, diagnostic criteria 49; see also hypoventilation disorders
sleep-related hypoxaemia disorder, diagnostic criteria 49; see also sleep hypoxaemia
sleep-related movement patterns/disorders diagnostic criteria 50
history-taking 9–10
polysomnography 14, 15, 16, 19–20
questionnaires 52
see also restless legs syndrome/periodic limb movement disorder
sleep restriction
delayed sleep phase syndrome 173
excessive daytime sleepiness 74
insomnia 149
shift work 175, 179
see also insufficient sleep syndrome
sleep starts 19, 50, 186
sleep terrors (night terrors) 9, 68–69, 185, 187
sleep–wake disturbances (SWDs)
multiple sclerosis 319, 321
stroke 301, 310
traumatic brain injury 291, 292, 294, 294–297
sleep–wake schedules 132; see also sleep hygiene
sleep–wake transitions 6, 9, 132, 163, 197, 268
sleep walking 9, 68–69, 184–185, 187
sleepiness
definitions 31–32
history-taking 130–131
as symptom of narcolepsy 133
see also excessive daytime sleepiness;
objective measurement, sleepiness/vigilance
SMAs (spinal muscular atrophies) 257
smoking, obstructive sleep apnoea 157
sniff nasal inspiratory pressure (SNIP) 255
snoring 53, 56, 57
CRSWD 171
diagnostic criteria 48, 49
headache disorders 265, 266, 271, 274
multiple sclerosis 320
myotonic dystrophy 245
neuromuscular diseases 253, 256
pharmacological treatment 68
polysomnography 16, 17, 22, 24, 25
sleep-disordered breathing 158, 164, 185, 215, 301
SNRIs (serotonin/norepinephrine reuptake inhibitors) 136, 196
sodium oxybate 66–67
excessive daytime sleepiness 78
narcolepsy 75, 136
REM parasomnias 68
SOREMPs see sleep onset REM periods
sound recordings, polysomnography 22
Spielman, A.J. 144
spinal muscular atrophies (SMAs) 257
spinocerebellar ataxias (SCAs) 233–236, 235
SSRIs (selective serotonin reuptake inhibitors) 38, 65, 69, 196
Stanford Sleepiness Scale (SSS) 50, 52
statins, sleep impacts 100, 111
status epilepticus in sleep, diagnostic criteria 51
stimulant medications 55
AASM guidelines 34
cancer patients 329, 330
excessive daytime sleepiness 75, 76, 139, 223, 246, 247, 249, 260, 293
idiopathic hypersomnia 137
narcolepsy 132, 136, 137
shift work 176
sleep impacts 100, 105, 214
stroke 310
traumatic brain injury 295, 297
STN (subthalamic) stimulation 221
STOP-Bang questionnaire 271
stress 100, 101, 145, 145; see also arousal disorders
stridor
dementia 236
Parkinson’s disease 212, 213, 215, 217, 218, 222, 224
polysomnography 22
stroke 301, 313
arousal disorders 306–307, 311–312
central sleep apnoea 163
clinical features of sleep disturbances 301–308
diagnosis/management 308–313, 310
hypersomnia 306–307, 312
insomnia 8, 144, 307–308, 312
sleep disordered breathing 157, 301–306, 303–305, 308–311, 311
sleep-related movement disorders 308, 312–313
Structured Interview for NFLE (SINFLE) 187
Structured Interview for Sleep Disorders according to DSM-III-R (SKID) 52, 53
subjective sleep experience
circadian rhythm sleep–wake disorders 178
fatigue 295, 296
insomnia 146, 147–148
objective tests 42, 53, 246
Parkinson’s disease 41, 179, 215, 221
pharmacological treatments 66, 94
RLS/PLMD 245, 248, 249
stroke patients 309
substance abuse 61, 62, 147, 175, 203
subthalamic (STN) stimulation 221
sundowning 178
supplemental oxygen therapy, neuromuscular disorders 260
suprachiasmatic nucleus (SCN) 86, 87, 93, 97, 169, 229, 232
sustained attention 32, 304; see also vigilance
Sustained Attention to Response Task (SART) 31, 32, 35–40, 37, 42, 43
suvorexant 93, 151
SWDs see sleep–wake disturbances
talking in sleep 9, 20, 50
teeth grinding see bruxism
temazepam 63, 64
tests for objective measurement see objective measurement
theophylline
central sleep apnoea 166
sleep impacts 100, 102, 113
3-P model (predisposing, precipitating and perpetuating factors), insomnia 144–145, 145
tolerance, drug holidays 75
topiramate 69, 96, 105, 285, 286
tracheostomy, neuromuscular disorders 260
traffic accident risk, obstructive sleep apnoea 157
traumatic brain injury 291, 297
circadian rhythm sleep–wake disorders 294, 297
diagnostic criteria 41, 51, 56–57
epidemiology of sleep disorders in 291–292, 292
excessive daytime sleepiness 76, 292–293, 294
fatigue 294, 295–296
hypersomnia 293–294, 294
insomnia 8, 144, 294, 296–297
pleiosomnia 293–295
trazodone 65–66, 104, 230, 310, 329
trend analysis, polysomnography 24, 26
tricyclic antidepressants 5, 66, 88, 136, 273; see also amitriptyline
triptans 79, 90
tumours/cancer 327, 338
brain tumours 51, 329–332, 338
effects of sleep on cancer development/progression 329
evaluative studies of sleep disturbances 327–329
see also paraneoplastic neurological syndromes
U
Ulanninna Narcolepsy Scale  52, 53

V
venlafaxine  69, 79, 104, 136, 217, 310, 312
ventrolateral preoptic area (VLPO)  96, 99
video-polysomnography (video-PSG)  19
nocturnal dissociative seizures  185
NFLE/SHE  282–284
parasomnias  190
standardisation of  14–15
videos of events
parasomnias  189–190
Parkinson's disease  217
vigabatrin, sleep impacts  99, 105
vigilance  6
definition  32
dementia  230
medication impacting on  73, 78, 91, 101, 132
stroke patients  312, 313
traumatic brain injury  292
see also objective measurement
viloxazine, sleep impacts  89
violent dream enactment  9, 14, 67–68, 216
viral anti-infectives, sleep impacts  115–117
VLPO (ventrolateral preoptic area)  96, 99
vocalisations  9, 20, 50
voltage-gated calcium channels  95, 118–119
voltage-gated potassium channels  335

W
wakefulness
acetylcholine  85–86, 86, 87
brain systems affecting  84
epilepsy  278
World Association of Sleep Medicine (WASM)  193

Z
zeitgeber, light as  170; see also melatonin
zopiclone/zolpidem  63, 64, 65, 221